Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.

Saved in:
Bibliographic Details
Title: Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.
Authors: Tokunaga E; National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka, Japan. erikotokunaga.nkcc@gmail.com., Iwata H; Aichi Cancer Center Hospital, Aichi, Japan., Itoh M; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan., Taira T; Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima, Japan., Toyama T; Nagoya City University Hospital, Aichi, Japan., Mizuno T; Mie University Hospital, Mie, Japan., Osaki A; Saitama Medical University International Medical Center, Saitama, Japan., Yanagita Y; Gunma Prefectural Cancer Center, Gunma, Japan., Nakamura S; Showa University Hospital, Tokyo, Japan., Nakamura R; Chiba Cancer Center, Chiba, Japan., Sambe T; Oncology R&D, AstraZeneca, Osaka, Japan., Ozaki T; Oncology R&D, AstraZeneca, Osaka, Japan., Schiavon G; Oncology R&D, AstraZeneca, Cambridge, UK., Howell SJ; The Christie NHS Foundation Trust, Manchester, UK., Toi M; Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Source: Breast cancer (Tokyo, Japan) [Breast Cancer] 2025 Jan; Vol. 32 (1), pp. 132-143. Date of Electronic Publication: 2024 Oct 08.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Maruzen Co Country of Publication: Japan NLM ID: 100888201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-4233 (Electronic) Linking ISSN: 13406868 NLM ISO Abbreviation: Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1880-4233
DOI:10.1007/s12282-024-01640-z